





UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/919,703	07/31/2001	Gerald Krystal	50216/003004	6548
21559	7590 09/26/2002			
	ELBING LLP	EXAMINER		
101 FEDERA BOSTON, M			LIU, SAMUEL W	
			ART UNIT	PAPER NUMBER
			1653	41.
			DATE MAILED: 09/26/2002	/

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
_	09/919,703	KRYSTAL ET AL.				
Office Action Summary	Examiner	Art Unit				
	Samuel W Liu	1653				
The MAILING DATE of this communication app Period for Reply	ears on the cover shet with the c	orrespondence address				
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply If NO period for reply is specified above, the maximum statutory period w. - Failure to reply within the set or extended period for reply will, by statute, - Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b). Status	36(a). In no event, however, may a reply be time within the statutory minimum of thirty (30) day rill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	nely filed s will be considered timely. the mailing date of this communication. D (35 U.S.C. § 133).				
1) Responsive to communication(s) filed on	·					
2a) This action is FINAL . 2b)区 Thi	is action is non-final.					
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213. Disposition of Claims						
4) ☐ Claim(s) <u>1-23</u> is/are pending in the application						
4a) Of the above claim(s) <u>none</u> is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6) Claim(s) is/are rejected.						
7) Claim(s) is/are objected to.						
8) Claim(s) 1-23 are subject to restriction and/or e	election requirement					
Application Papers						
9)☐ The specification is objected to by the Examiner	r.					
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
11)☐ The proposed drawing correction filed on	_is: a)□ approved b)□ disappro	oved by the Examiner.				
If approved, corrected drawings are required in reply to this Office action.						
12) The oath or declaration is objected to by the Examiner.						
Priority under 35 U.S.C. §§ 119 and 120						
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
a) All b) Some * c) None of:						
 Certified copies of the priority documents 	s have been received.					
Certified copies of the priority documents	s have been received in Applicati	on No				
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 						
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).						
 a) ☐ The translation of the foreign language pro 15)☐ Acknowledgment is made of a claim for domesting 						
Attachment(s)						
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Informal F	Patent Application (PTO-152)				
S. Patent and Trademark Office						

Application/Control Number: 09/919,703

Art Unit: 1653

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- Claims 1-20, drawn to a method of treating cell death, are classified in class 530, subclass 300, 333 and 402, class 514, subclass 8, 13 and 17, class 424, subclass 93.7 and 278.1, and class 930, subclass 20.
- II. Claims 22--23, drawn to a pharmaceutical composition, are classified in class 530, subclass 300 and 402, class 514, subclass 8, 13 and 17, class 424, subclass 278.1.

The inventions are distinct, each from the other because of the following reasons:

Invention I is related to Inventions II as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case, the polypeptide can be used in proteinchip array to investigating signal transduction pathway, for example.

Additional Election Under 35 USC 121

Regardless of the elected group, applicant is required under 35 US 121 (1) to elect a single disclosed peptide to which claims are restricted; and (2) to list all claims readable thereon including those subsequently added.

- (1) If Group I is elected, applicants are required to elect:
- (i) one polypeptide from SEQ ID NO. 1-8 (see Claims 2, 3, 16 and 17);

Application/Control Number: 09/919,703

Art Unit: 1653

(ii) one disease/disorder state form Claim 18, because each disease/disorder state has different or distinct pathological characteristics, requires different therapeutic procedure and has distinct outcome of the treatment.

(2) If Group II is elected, applicants are required to elect one polypeptide from SEQ ID NO. 1-8 (see Claims 22 and 23).

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art shown by their different classification, art recognized divergent subject matter, separate search, restriction for examination purposes as indicated is proper.

Applicant is required that a response to this requirement must include an identification of the members that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Samuel Wei Liu, Ph.D. whose telephone number is 703-306-3483. The examiner can normally be reached Monday-Friday 9:00 -5:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Dr. Christopher Low can be reached on (703) 308-2923. The fax phone numbers for the organization where this application or proceeding is assigned are 703-308-4242 for regular

Application/Control Number: 09/919,703

Art Unit: 1653

Page 4

communication and (703) 305-3014 for the after final communication. Any inquiry of a general nature or relating to the status of this application should be directed to the Technology Center 1600 receptionist whose telephone number is (703) 308-0196.

KAREN COCHRANE CARLSON, PH.D
PRIMARY EXAMINER

SWL

September 18, 2002